- Active, not recruiting
NCT01857115: Phase 1/2: EMN - Study of Wkly Carfilzomib, Cyclophosphamide and Dexamethasone In NDMM
Updated: Sep 25, 2022
wCCyd
EMN
European Myeloma Network
NCT01857115: Phase 1/2: Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) (wCCyd)
Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) (wCCyd)
This protocol is a phase I/II multicenter study designed to assess the safety and the efficacy of the proposed combinations as up-front treatment in elderly Multiple Myeloma (MM) patients.
Sponsor
Collaborator
Fondazione EMN Italy Onlus
ClinicalTrials.gov Identifier: NCT01857115
Official Title: A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS
First Posted : May 20, 2013
Click here for the details on ClinicalTrials.gov
Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Dexamethasone
Haematologica;2021
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
Haematologica; 2020
Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
Locations
Italy